MEDINCELL Stock: Up 2.54% at Midday, 5.73% Increase Over the Week
The stock of French biotech company MedinCell continues its upward trend this Thursday, October 23, at midday. At EUR 34.70, the stock has gained 2.54% compared to the previous day, marking a trend of increase that extends well beyond the week. Over the year, the performance has reached 119.90%, significantly outperforming the CAC 40, which has only gained 9.44% over twelve months.
Market Conditions Favor MedinCell's Rise
MedinCell crosses the EUR 34.70 mark under generally favorable market conditions. The CAC 40 is up by 0.48% at 8,246.11 points on this October 23, creating a conducive environment for tech and biotech stocks. In the short term, the stock demonstrates undeniable vitality. The past week shows a progression of 5.73%, while the three-month performance reaches 122%. These levels indicate a continuous acceleration since the beginning of the year, with a surge of 103.97% since January 1, 2025. However, the intensity of trading reveals some caution. The traded share capital capped at 0.22% remains moderate, indicating that this rise is occurring on limited trading volumes. This element somewhat tempers the apparent enthusiasm of the price movement, suggesting that the bullish trend is occurring under conditions of reduced liquidity. Institutional and retail investors seem only marginally active on the stock at this time of the day.
Positive Developments Boost Stock Performance
The stock's evolution is set against a backdrop of several favorable events. On October 10, the FDA approved the indication extension for UZEDY®, a product developed in partnership with Teva for the treatment of type I bipolar disorder. This approval was a major catalyst for the stock, leading to a rise of 21.06% on October 13 according to available data. Earlier, on September 23, the Canadian authorization of LONGAVO®, a long-acting injectable formulation of risperidone, also marked a positive milestone. Concurrently, MedinCell will participate in the Truist Securities Biopharma Symposium 2025 in New York this week, an opportunity to showcase its strategy and therapeutic portfolio.
Technical Analysis Shows Mixed Signals
Technically, the stock displays mixed signals. The Relative Strength Index (RSI) peaks at 77, indicating a pronounced overbought situation. The 50-day and 200-day moving averages are set at EUR 22.72 and EUR 17.20, respectively, significantly below the current price, highlighting an established upward trend. The MACD (3.68) remains above its signal line (3.31), confirming a positive momentum. Technically, resistance is set at EUR 35.50, slightly above current levels, while support is at EUR 19.45. The Bollinger Bands frame the stock between EUR 20.01 and EUR 37.83. The stock remains particularly volatile with an annualized volatility coefficient of 21.32% over a month. The low beta (0.14) indicates a low correlation with the general market index.
